Himax Technologies, Inc (NASDAQ: HIMX) reported a second-quarter FY23 revenue decline of 24.8% year-on-year to $235.03 million, marginally missing the consensus of $235.6 million.
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ: ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.
https://www.japantimes.co.jp/news/2023/09/05/japan/osaka-casino-delay/#:~:text=The%20Osaka%20prefectural%20and%20municipal,around%20autumn%20or%20winter%202029.
The Osaka prefectural and municipal governments